These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 23466899)

  • 1. Clinically meaningful responses to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer.
    Klimant E; Markman M; Albu DM
    Case Rep Oncol; 2013 Jan; 6(1):72-7. PubMed ID: 23466899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Near-Complete Response to Treatment with Gemcitabine plus nab (®)-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report.
    Shakir AR
    Case Rep Oncol; 2014 Sep; 7(3):711-7. PubMed ID: 25493084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
    Liu GF; Li GJ; Zhao H
    J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Brus C; Saif MW
    JOP; 2010 Jul; 11(4):321-3. PubMed ID: 20601802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
    Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
    J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma.
    Bukhari N; Abdalla K; Ibnshamsa F; Alselwi W; Al-Shakir S; Alqahtani M
    Cureus; 2021 Oct; 13(10):e18756. PubMed ID: 34796055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer.
    Picozzi V; Narayanan S; Henry Hu X; Vacirca J
    J Gastrointest Cancer; 2017 Mar; 48(1):103-109. PubMed ID: 28028766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
    Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
    Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2.
    Martín AJ; Alfonso PG; Rupérez AB; Jiménez MM
    Oncol Lett; 2016 Jul; 12(1):727-730. PubMed ID: 27347207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Bayesian Analysis.
    Zhang S; Tian Y; Xie S; Zhang J; Zhao J; Chen Y; Wang C
    Intern Med; 2018 Aug; ():. PubMed ID: 30146578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative gemcitabine and oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma.
    Di Marco M; Vecchiarelli S; Macchini M; Pezzilli R; Santini D; Casadei R; Calculli L; Sina S; Panzacchi R; Ricci C; Grassi E; Minni F; Biasco G
    Case Rep Gastroenterol; 2012 May; 6(2):530-7. PubMed ID: 22949893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
    Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
    Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
    Okano N; Morizane C; Nomura S; Takahashi H; Tsumura H; Satake H; Mizuno N; Tsuji K; Shioji K; Asagi A; Yasui K; Kitagawa S; Kashiwada T; Ishiguro A; Kanai M; Ueno M; Ogura T; Shimizu S; Tobimatsu K; Motoya M; Nakashima K; Ikeda M; Okusaka T; Furuse J
    Int J Clin Oncol; 2020 Oct; 25(10):1835-1843. PubMed ID: 32535711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic INI1-deficient undifferentiated rhabdoid carcinoma achieves complete clinical response on gemcitabine and nab-paclitaxel following immediate progression on FOLFIRINOX: a case report.
    King DA; Rahalkar S; Bingham DB; Fisher GA
    J Gastrointest Oncol; 2021 Apr; 12(2):874-879. PubMed ID: 34012674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
    Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
    Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
    Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxanes: impact on pancreatic cancer.
    Chiorean EG; Von Hoff DD
    Anticancer Drugs; 2014 May; 25(5):584-92. PubMed ID: 24463484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for pancreatic cancer.
    Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
    Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.